Navigation Links
IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
Date:3/20/2008

quality of life."

Study background

The compassionate access study is being conducted initially at M. D. Anderson and Memorial-Sloan Kettering Cancer Center in New York. Eligible patients will have a confirmed diagnosis of high grade osteosarcoma with relapsed or recurrent disease, locally or metastatic, with resectable or not completely resectable disease, or who are unable to complete recommended chemotherapy due to toxicity.

Patients enrolled in the study will receive L-MTP-PE over one hour two times a week, at least three days apart, for 12 weeks (3 months). Patients will then receive L-MTP-PE once a week for the next 24 weeks (6 months). Additionally, patients may receive other treatments in combination with L-MTP-PE.

In addition to providing access to the drug, the objectives of the study are to provide supplemental safety and tolerability data for L-MTP-PE and supplemental pharmacokinetic information in a small patient subset.

For more information about the study please visit http://www.clinicaltrials.gov.

Update on L-MTP-PE Regulatory Status

The Company recently announced that following presentation of data at an oral explanation hearing before the Committee for Medicinal Products for Human Use (CHMP), the CHMP determined in a non-binding opinion that L-MTPE-PE suggested a possible clinical benefit in terms of survival and granted the Company a clock stop, or time extension. The clock stop will allow the Company additional time to respond to all the remaining questions regarding the marketing authorization application for L-MTP-PE (MAA). The CHMP has requested clarification of the existing data in order to gain assurance about the quality of the data before drawing any final conclusions from the data presented. In addition, the Company is required to address a number of remaining questions relating to chemistry, manufacturing and controls (CMC). The Comp
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
2. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
3. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
4. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
5. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
8. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
9. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Echo Therapeutics, Inc. (NASDAQ: ECTE ... recent unauthorized public statements relating to Echo that have ... Shepard M. Goldberg, two members of the Echo Board ... the Echo Board by an affiliate of Platinum Management ... in numerous unauthorized public communications targeted at Echo stockholders, ...
(Date:10/2/2014)... , Oct. 2, 2014 A new Insights ... entitled, " Adherence: why it,s so hard and what ... key research findings on medication adherence and lays out ... percent through new interventions by 2017. For the past ... focused on building the body of scientific knowledge available ...
(Date:10/2/2014)... , Oct. 2, 2014   Softworld, Inc. ... a new practice solely focused on the specific needs ... While Softworld has already been highly successful in ... their additional capabilities to support the quality, regulatory, and ... is now a combination of the current Biometric team ...
Breaking Medicine Technology:Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 2Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 3Echo Therapeutics Comments On Unauthorized Public Statements By Michael M. Goldberg, M.D. And Shepard M. Goldberg 4CVS Health Insights Report Tackles Complex Issue of Medication Adherence 2CVS Health Insights Report Tackles Complex Issue of Medication Adherence 3Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2
... SAN DIEGO, Jan. 7, 2012  Neurocrine Biosciences, Inc. (Nasdaq: ... its academic founder and member of the Board of ... week.  He was a thoughtful leader with an incredible ... was matched by his terrific wit and disarming good ...
... N.Y., Jan. 6, 2012  VirtualScopics, Inc., (NASDAQ: ... the pharmaceutical, biotechnology and medical device industries, announced today ... from the NASDAQ Stock Market indicating that the Company,s ... consecutive business days.  NASDAQ Marketplace Rule 5550(a)(2)requires a $1.00 ...
Cached Medicine Technology:VirtualScopics Announces Receipt of Notice from Nasdaq 2VirtualScopics Announces Receipt of Notice from Nasdaq 3
(Date:10/1/2014)... that more than 80 per cent of bowel cancers ... found that medicines called ,JAK inhibitors, halted tumour growth ... present in more than 80 per cent of bowel ... in clinical trials, for diseases including rheumatoid arthritis, psoriasis, ... the second-most common cancer in Australia with nearly 17,000 ...
(Date:10/1/2014)... Engineering and Physical Sciences Research Council (EPSRC) will ... industrial control systems which run, for example, manufacturing ... rail network. , The research will help ... infiltrating the systems behind our critical national infrastructure. ... Control Systems (RITICS), based at Imperial College London, ...
(Date:10/1/2014)... that encourages people to keep their "eyes on the ... exercise. When walking, staying focused on a specific target ... and help people walk there faster, psychology researchers have ... while looking around the environment naturally, offers a new ... are less interested in exercise if physical activity seems ...
(Date:10/1/2014)... Insuranceragents.info has released a new ... insurance plan for vulnerable family members. , Life insurance ... Providers in the family should always carry a life ... for the rest of the family. , Clients ... benefit more from temporary coverage or from a permanent ...
(Date:10/1/2014)... Nev. (PRWEB) October 01, 2014 First ... measuring abnormal circadian cellular changes throughout the body, announced ... Inc. to better address the company’s breadth of upcoming ... early breast cancer screening technology. , “Our initial focus ... cancer system which detects abnormal circadian cellular changes over ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4
... The ban on bird shows in Britain has been lifted on ... ,Various events such as pigeon racing, falconry and other ... to this bird flu scare in October which was detected in ... ,But now since no single case of bird flu was ...
... Texas has revealed that men suffering from impotence/erectile dysfunction ... their counterparts. // More than 100 million men ... with approximately 10 million in the US alone. ... disease including age, smoking, diabetes, heart disease, depression and ...
... in the latest issue of American Journal of Preventive Medicine ... and heart disease. ,These conclusions were arrived at ... Health at the Centers for Disease Control and Prevention. They ... 1999-2002 Behavioral Risk Factor Surveillance System survey. This particular survey ...
... has revealed that a version of the Viagra pill meant for ... larger when compared to that of men, but it also // ... to Ellis. The desire, arousal and pain experienced by the woman ... make it all the more difficult to develop it. ...
... hospitals are flooded with patients with psychiatric disorders. The number ... in the past 4 years. ,This shows ... facilities. ,According to the Australian Institute of Health ... psychiatric hospitals decreased by 5%. ,But the pressure ...
... of Camembert cheese with the microorganism E.coli, products containing ... potential risk of food poisoning. The Food Standards Agency ... this cheese. ,A form of E.coli known ... has been believed to be responsible for the contamination. ...
Cached Medicine News:Health News:Community hospitals inundated with Psychiatric care cases (12%) 2
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
Medicine Products: